allergic reaction to semaglutide Exploring Semaglutide-Induced Rash: Causes, Prevention, and Treatment Anyone end up with hives

Decreased whole-brain functional connectivity in GLP-1R KO mice Previous studies have suggested a link between functional connectivity and the use of glucose in the brain [27, 51, 52]

Clinical studies, including the STEP 1 extension trial, have demonstrated that patients who discontinue GLP-1 receptor agonists often regain a significant portion of lost weightsometimes two-thirds or morewithin one year of stopping treatment

The pivotal Phase 2 trial a 48-week study published in The New England Journal of Medicine in 2023 produced these results in adults with obesity (and no diabetes), at the highest dose of 12 mg weekly: Average weight loss of around 24% from baseline A clear dose-response, with even the 4 mg dose producing roughly 17% weight loss Continued weight loss right up to the 48-week endpoint, with no plateau in sight For context, similar Phase 2 data for Wegovy showed around 15% weight loss at 68 weeks

It has said it expects to file for approval as early as this year

It gives you the dessert vibe without turning into a full sugar bomb

For context, semaglutide 2.4 mg (Wegovy) demonstrated approximately 15% mean weight loss in the STEP 1 trial ( NEJM , 2021), while tirzepatide achieved up to approximately 22% in the SURMOUNT-1 trial ( NEJM , 2022)